A股烟草板块持续走强，华宝股份、劲嘉股份双双涨停，华业香料涨超8%，顺灏股份涨超7%，陕西金 叶、金城医药跟涨。 ...

2025年5月30日，公司与中国工商银行股份有限公司淄博淄川支行签署了《保 证合同》，为金城生物借款提供连带责任担保，担保债权之最高本金余额为人民币 500万元整(大写：伍佰万元整)。 | 被担保方 | 经审议的 | | 本次担保前对 | | 本次担保后对 | | 已使用担保额 | 剩余可用 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 担保额度 | | 被担保方的担 | | 被担保方的担 | | 度（含本次） | 额度 | | | | | | 保余额 | | 保余额 | | | | | | 金城生物 | 20,000 | 万元 | 5,650 | 万元 | 6,150 | 万元 | 11,500 万元 | 8,500 | 万元 | 二、被担保人基本情况 证券代码：300233 证券简称：金城医药 公告编号：2025-044 （一）基本信息 山东金城医药集团股份有限公司 6、经营范围：许可项目：药品生产；药品批发；食品添加剂生产；饲料添加 剂生产；食品销售；食品生产；药品进出口；保健食品生产；饲料生产。（依法须 经批 ...

Group 1 - The chemical pharmaceutical sector experienced a short-term surge, with Hainan Haiyao (000566) and Huahai Pharmaceutical (600521) hitting the daily limit up, indicating strong market interest [1] - Tianyu Co., Ltd. (300702) saw an increase of over 10%, reflecting positive investor sentiment in the sector [1] - Other companies such as Jincheng Pharmaceutical (300233), Saito Biological (300583), Weichip Bio, Luyuan Pharmaceutical (600789), and Nawei Technology also experienced gains, suggesting a broader rally in the industry [1]

注：汇海医药尚未发生实际借款业务，故本次担保后对被担保方的担保余额尚未发生变动。 证券代码：300233 证券简称：金城医药 公告编号：2025-043 山东金城医药集团股份有限公司 关于为子公司提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）第六届董事会第十四次 会议审议通过了《关于预计2025年度担保额度的议案》，并经公司2024年年度股东 大会审议通过。公司及子公司对外担保总额不超过人民币15.3亿元，其中为山东汇 海医药化工有限公司（以下简称"汇海医药"）提供担保不超过人民币4亿元。 一、担保情况概述 2025年5月26日，公司与招商银行股份有限公司淄博分行签署了《最高额不可 撤销担保书》，为汇海医药借款提供连带责任担保，担保债权之最高本金余额为人 民币5,000万元整(大写：伍仟万元整)。 | 被担保方 | 经审议的 | 本次担保前 | 本次担保后 | 已使用担保 | 剩余可用 | | --- | --- | --- | --- | --- | --- | | | 担保额度 | 对被担保 ...

Group 1 - The genetically modified (GM) concept sector declined by 2.81%, ranking among the top declines in concept sectors as of the market close on May 22 [1] - Key companies within the GM sector that experienced significant declines include KQ Bio, Jincheng Pharmaceutical, and Batian Agricultural [1] - The GM concept sector saw a net outflow of 171 million yuan in main funds today, with 13 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The stock with the highest net outflow was Dabeinong, with a net outflow of 45.6868 million yuan, followed by Jincheng Pharmaceutical and Batian Agricultural with net outflows of 35.9827 million yuan and 21.2855 million yuan, respectively [2] - Other companies with notable net outflows include Qianyuan High-Tech and Nongfa Seed Industry, with outflows of 13.8355 million yuan and 11.1082 million yuan, respectively [2] - Conversely, Shennong Seed Industry and Fengle Seed Industry were among the few stocks with net inflows, receiving 9.7587 million yuan and 0.8193 million yuan, respectively [2]

Group 1 - The concept of ergot sulfur has gained popularity, leading to significant stock price movements among related companies, with some experiencing a daily limit increase [1][3] - Kelong Pharmaceutical has been actively promoting ergot sulfur, with its chairman showcasing the product's potential in an advertisement, which has contributed to the surge in related stocks [1][2] - Several companies have responded to investor inquiries regarding their involvement with ergot sulfur, indicating that the revenue from products containing this ingredient is currently low and has minimal impact on overall performance [3] Group 2 - Kelong Pharmaceutical has been focusing on the health industry for seven years, emphasizing the commercialization of ergot sulfur as a key growth factor [2] - Other companies, such as Haizheng Pharmaceutical and Wanbang Pharmaceutical, are also exploring the potential applications of ergot sulfur, with ongoing research and development efforts [3]

Group 1: Company Operations and Product Development - The production of astaxanthin is currently undergoing safety certification review, with plans for market launch initially set for 2024 but now delayed to 2025 [2] - The company is actively communicating to expedite the approval process for astaxanthin [2] - Glutathione is being positioned as a raw material for downstream pharmaceutical production, with licenses obtained for its use in functional foods and health products [3] Group 2: Market Conditions and Financial Performance - The company is managing stable raw material costs and enhancing cost control measures to mitigate the impact of fluctuating crude oil prices on profits [2] - The first quarter profit saw a year-on-year decline, attributed to price reductions in some products due to procurement policies and intensified industry competition [5] - The overall business impact from US-China trade tensions is currently assessed as minimal, with ongoing monitoring of tariff policy changes [5] Group 3: Product Pricing and Market Demand - The price of glutathione has not seen significant changes recently, despite market fluctuations and varying customer requirements [5] - The company is exploring the potential for glutathione to be classified as a new resource food, which could significantly increase demand [2] - The company is tracking developments in the new tobacco sector, focusing on nicotine therapy and harm reduction [5]

Group 1 - Vanke A's largest shareholder, Shenzhen Metro Group, plans to provide a loan of up to 1.55 billion yuan to repay the company's bonds [1] - Yidelong reported a net profit of 41.77 million yuan for Q1 2025, a year-on-year increase of 34.19% [1] - Overseas Chinese Town A achieved a contract sales amount of 1.78 billion yuan in April, a year-on-year increase of 10% [1][2] Group 2 - Dajin Heavy Industry's subsidiary signed a contract worth approximately 1 billion yuan for an offshore wind power project with a European energy company [4] - Liao Port Co. announced the resignation of Chairman Wang Zhixian due to reaching retirement age [4] - China Energy Construction's application for a specific stock issuance has been approved by the Shanghai Stock Exchange [6] Group 3 - Xinhua Insurance reported a 27% year-on-year increase in premium income from January to April, totaling 85.38 billion yuan [11] - 吉祥航空's passenger turnover increased by 6.34% in April, with a seat occupancy rate of 86.16% [13] - New City Holdings reported a contract sales amount of approximately 1.76 billion yuan in April, a year-on-year decrease of 52.46% [28] Group 4 - Three Yuan Bio announced a preliminary ruling of a 3.49% countervailing duty on its products in the U.S. [23] - Shanghai Pharmaceutical's product, Wengjing Decoction Granules, has been approved for production [20] - A strategic cooperation agreement was signed between *ST Dali and Zhuhai Yunzhou Intelligent Technology Co., Ltd. to promote the development of intelligent unmanned equipment [22] Group 5 - The construction of the automotive lightweight forging precision processing project by Sanlian Forging has been completed [25] - The company Tianma Technology reported an output of approximately 1,480.16 tons of eel in April [18][19] - The company Victory Technology plans to invest up to 3 billion yuan for share repurchase [42]

Group 1 - Tonghua Dongbao has received approval from Nicaragua's National Health Regulatory Authority for its recombinant human insulin injection, which is expected to enhance the company's international market presence and brand image [1] - The diabetes patient population in Nicaragua is projected to reach 377,000 by 2024, with an 8.7% prevalence rate among adults aged 20-79, indicating a significant market opportunity for the company [1] - The average annual expenditure per diabetes patient in Nicaragua is estimated at $587, highlighting the potential revenue generation from the new product [1] Group 2 - Haobor's response to the 2024 annual report inquiry reflects the company's commitment to regulatory compliance and transparency, addressing concerns regarding its distribution model and dealer management [2] - The detailed analysis of dealer numbers and management policies demonstrates the stability and rationality of the company's business model, which may alleviate investor concerns [2] - Continuous optimization of dealer management is expected to provide strong support for the company's long-term development [2] Group 3 - Kangji Medical has decided to terminate the sale of a subsidiary and has reached a settlement agreement with the buyer, which includes the return of company records and a refund of 5 million yuan [3] - The company expects to realize approximately 39.3 million yuan in gains from a land recovery agreement with government agencies, indicating effective management of complex transactions [3] - The resolution of this transaction is likely to stabilize investor confidence and positively impact the company's long-term growth prospects [3] Group 4 - Jincheng Pharmaceutical has signed a licensing and distribution agreement with UK-based Theramex HQ UK Limited for the hormone replacement therapy product Bijuva, aimed at addressing estrogen deficiency symptoms in postmenopausal women [4] - This collaboration aligns with the company's strategy to enhance its offerings in women's health and strengthen partnerships with international pharmaceutical firms [4] - The agreement is expected to expand the company's product portfolio in the women's health sector and improve its brand influence in this market [4]

金城医药：与Theramex签署权益许可和经销协议 智通财经5月13日电，金城医药(300233.SZ)公告称，金城医药近日与Theramex HQ UK Limited签署了 《权益许可和经销协议》，获得用于绝经后妇女雌激素缺乏症状的连续联合激素替代疗法（HRT）的雌 二醇黄体酮软胶囊（Bijuva）在中国境内（包括中国大陆、香港和澳门）的独家排他的商业化权益。此 次合作不涉及关联交易，亦不构成重大资产重组。协议签署预计不会对公司本年度财务状况和经营业绩 构成重大影响。 ...